Postmenopausal osteoporosis and alendronate.

Osteoporosis is a systemic metabolic disorder associated with a decreased bone mass and resistance. Bisphosphonates suppress bone resorption and bone turnover by a mechanism that depends on their structure. They are characterized by low gastrointestinal absorption. In postmenopausal women, alendronate (ALN) reduces bone resorption markers and increases bone mineral density (BMD) in the lumbar spine, femoral neck, and total body. Individuals receiving ALN have been studied for up to 10 years with an apparent linear increase in BMD over that time period estimated at 13.7% at the lumbar spine. Treatment with ALN reduced the risk of both vertebral and non-vertebral fractures, including hip fractures, in postmenopausal women with osteoporosis. Direct comparisons of the results obtained with different antiresortive agents is difficult, because the designs of the respective studies, populations and other factors. However, the meta-analysis of available publications seems to indicate that ALN reduces the relative risk of vertebral fractures in a greater proportion than any other agent. Furthermore, ALN prevents the reduction in BMD after hormone replacement therapy discontinuation.

[1]  F. Orio,et al.  Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[2]  S. Wimalawansa.  A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. , 1998, The American journal of medicine.

[3]  R. Francis,et al.  The increasing use of peripheral bone densitometry , 2000, BMJ : British Medical Journal.

[4]  S. Greenspan,et al.  Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. , 2002, Mayo Clinic proceedings.

[5]  D. Burr,et al.  Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. , 2001, Bone.

[6]  R. Rizzoli.  Two‐Year Results of Once‐Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[8]  C. Coupland,et al.  Alendronate and EstrogenProgestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial , 1999, Annals of Internal Medicine.

[9]  G. Guyatt,et al.  Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. , 2002, Endocrine reviews.

[10]  Graciela Demirdjian.  Medicina basada en la evidencia , 2001 .

[11]  Faustino R. Pérez-López,et al.  Tratamiento hormonal de la menopausia: controversias, precisiones y perspectivas , 2003 .

[12]  R. Robbins,et al.  Developments in the Therapeutic Applications of Bisphosphonates , 1999, Journal of clinical pharmacology.

[13]  E. Barrett-Connor,et al.  Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. , 2002, Archives of internal medicine.

[14]  Michael C. Nevitt,et al.  Fracture Risk Reduction With Alendronate in Women With Osteoporosis: The Fracture Intervention Trial , 2001 .

[15]  D. Felsenberg,et al.  Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study , 1999, Osteoporosis International.

[16]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[17]  R. Recker,et al.  Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  J. Gallagher,et al.  Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. , 2001, The Journal of clinical endocrinology and metabolism.

[19]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[20]  D. Torgerson,et al.  Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. , 2001, JAMA.

[21]  K. Faulkner,et al.  Bone Matters: Are Density Increases Necessary to Reduce Fracture Risk? , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  Screening for osteopenia and osteoporosis: Selection by body composition , 1996 .

[23]  C. Cooper,et al.  Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. , 2003, Bone.

[24]  M. Hochberg,et al.  Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial , 2002, Journal of the American Geriatrics Society.

[25]  D. Burr,et al.  Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  S. Shakir,et al.  Pharmacovigilance study of alendronate in England , 2003, Osteoporosis International.

[27]  G Boivin,et al.  Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. , 1997, Bone.

[28]  L. Weinstein,et al.  Identification of at-risk women for osteoporosis screening. , 2000, American journal of obstetrics and gynecology.

[29]  J. Bilezikian,et al.  Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. , 2002, The Journal of clinical endocrinology and metabolism.

[30]  P Geusens,et al.  Risk of new vertebral fracture in the year following a fracture. , 2001, JAMA.

[31]  R. Lindsay,et al.  Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. , 1999, The Journal of clinical endocrinology and metabolism.

[32]  B. Walsh,et al.  Comparison of Alendronate and Intranasal Calcitonin for Treatment of Osteoporosis in Postmenopausal Women , 2000 .

[33]  D. McTavish,et al.  Alendronate , 1997, Drugs.

[34]  M. Hochberg,et al.  Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  Jacques P. Brown,et al.  Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. , 2001, JAMA.

[36]  B. Stuckey,et al.  Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. , 2003, Archives of internal medicine.

[37]  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004 .

[38]  M. McClung.  Bisphosphonates in osteoporosis: recent clinical experience , 2000, Expert opinion on pharmacotherapy.

[39]  P. Meunier,et al.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. , 2000, Bone.

[40]  N. Watts.  Treatment of osteoporosis with bisphosphonates. , 1994, Rheumatic Disease Clinics of North America.

[41]  J. Orloff,et al.  Therapeutic Equivalence of Alendronate 35 Milligrams Once Weekly and 5 Milligrams Daily in the Prevention of Postmenopausal Osteoporosis , 2003, Obstetrics and gynecology.

[42]  B. Walsh,et al.  Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. , 2000, The Journal of clinical endocrinology and metabolism.

[43]  P. Roberson,et al.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. , 1999, The Journal of clinical investigation.

[44]  Ailsa E Gebbie,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.

[45]  D. Kiel,et al.  Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. , 2000 .

[46]  R. Stine,et al.  Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. , 1998, The American journal of managed care.

[47]  H. Nelson.  Screening for Postmenopausal Osteoporosis , 2003 .

[48]  P. Sambrook,et al.  Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[49]  S. Ortolani,et al.  Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. , 1995, Bone.

[50]  C. Coupland,et al.  Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. , 1999, Annals of internal medicine.

[51]  J. Rodriguez-Portales,et al.  Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. , 2000, The Journal of clinical endocrinology and metabolism.

[52]  Sundeep Khosla,et al.  Sex steroids and the construction and conservation of the adult skeleton. , 2002, Endocrine reviews.

[53]  R. Moynihan,et al.  On music , 2002, BMJ : British Medical Journal.

[54]  Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. , 2002, Endocrine reviews.

[55]  J. Cauley,et al.  Risk of Mortality Following Clinical Fractures , 2000, Osteoporosis International.

[56]  I. Reid,et al.  Prospective 10‐year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy , 2002, Clinical endocrinology.

[57]  S. Cummings,et al.  Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. , 1999, Arthritis and rheumatism.

[58]  M. Cohen-Solal,et al.  [Genetics of osteoporosis]. , 2004, La Revue de medecine interne.

[59]  D. Hans,et al.  How Hip and Whole-Body Bone Mineral Density Predict Hip Fracture in Elderly Women: The EPIDOS Prospective Study , 1998, Osteoporosis International.

[60]  O. Johnell,et al.  Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[61]  P. Miller,et al.  Antifracture efficacy of antiresorptive agents are related to changes in bone density. , 2000, The Journal of clinical endocrinology and metabolism.

[62]  M. Stone.  Once-weekly treatment for osteoporosis. , 2002, Hospital medicine.

[63]  J. Adachi,et al.  Long-Term Tolerability of the Bisphosphonates in Postmenopausal Osteoporosis , 2002, Drug safety.

[64]  J. Reginster,et al.  Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study , 2003, Current medical research and opinion.

[65]  J. Rodriguez-Portales,et al.  Ten years' experience with alendronate for osteoporosis in postmenopausal women. , 2004, The New England journal of medicine.